Sk Biopharmaceuticals Co Ltd (326030) — Cash Flow Reinvestment Rate

Latest as of March 2026: 0.17x

Sk Biopharmaceuticals Co Ltd (326030) has a Cash Flow Reinvestment Rate of 0.17x as of March 2026, reinvesting ₩3.01 Billion (capex ₩2.94 Billion plus investments ₩-62.91 Million) from operating cash flow of ₩17.92 Billion. See Sk Biopharmaceuticals Co Ltd free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

0.17x

(Capex + Investments) / Operating CF

Total Reinvested

₩3.01 Billion

Capex + Investments

Operating Cash Flow

₩17.92 Billion

KRW

Capital Expenditures

₩2.94 Billion

KRW

Sk Biopharmaceuticals Co Ltd Cash Flow Reinvestment Rate (2024–2025)

Historical reinvestment intensity for Sk Biopharmaceuticals Co Ltd across 2 annual periods. For the full cash flow conversion analysis, see 326030 operating cash flow.

Annual Cash Flow Reinvestment Rate for Sk Biopharmaceuticals Co Ltd (2024–2025)

Year-by-year capital reinvestment analysis for Sk Biopharmaceuticals Co Ltd. See Sk Biopharmaceuticals Co Ltd free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.

Year	Reinvestment Rate	Total Reinvested (KRW)	Operating CF	Capex	YoY Change
2025	0.19x	₩33.88 Billion	₩176.33 Billion	₩29.51 Billion	▲ +7.7%
2024	0.18x	₩16.93 Billion	₩94.90 Billion	₩13.42 Billion	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow